Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128

Showing 26-50 of 128 citing articles:

Integrating CRISPR Technology with Key Genetic Markers in Pancreatic Cancer: A New Frontier in Targeted Therapies
Dimitrios Stefanoudakis
SynBio (2025) Vol. 3, Iss. 1, pp. 1-1
Open Access
Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with EGFR or KRAS Mutation
Jialiang Wang, Chang Guo, Jiexiao Wang, et al.
Cancer Control (2025) Vol. 32
Open Access
Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non-small cell lung cancer
Xiaodong Wang, Jia-Hong Lin, Ming-Hao Hu
Journal of Biological Chemistry (2025), pp. 108164-108164
Open Access
HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms
Shruti Ghai, Rejina Shrestha, Kuo‐Hui Su
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
Long-term survival with pemetrexed-based chemotherapy in a patient with metastatic lung adenocarcinoma of unclear primary origin harboring MTHFR C677T(T/T) mutation: a case report
Yuan Yu, Nanjing Li, Jin Wang
Frontiers in Oncology (2025) Vol. 14
Open Access
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Toshifumi Doi, Takeshi Ishikawa, Michihisa Moriguchi, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
An innovative approach to development of new pyrazolylquinolin-2-one hybrids as dual EGFR and BRAFV600E inhibitors
Mohamed M. Hawwas, Ahmed S. Mancy, Mohamed Ramadan, et al.
Molecular Diversity (2025)
Open Access
Dynamic Coupling and Entropy Changes in KRAS G12D Mutation: Insights into Molecular Flexibility, Allostery and Function
Aysima Hacisuleyman, Deniz Yüret, Burak Erman
Journal of Molecular Biology (2025), pp. 169075-169075
Open Access
Evaluation of the Inhibitory Potential of Apigenin and Related Flavonoids on Various Proteins Associated with Human Diseases Using AutoDock
Tanat Peanlikhit, Uma K. Aryal, James S. Welsh, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2548-2548
Open Access
Autocrine p40 enhances the efficacy of CLDN18.2 CAR-T cells in gastrointestinal cancer
Weidong Zhang, Miao Zeng, Xingyu Ma, et al.
Genome Instability & Disease (2025)
Closed Access
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Jianzhuang Wu, Kexin Xie, Yixuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Joyeeta Roy, Rima Mouawad, Armita Kyani, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Antiproliferative and Apoptotic Efficacy of Nano‐PLGA Encapsulated Quercetin Molecules by Downregulation of Akt in K‐ras Mutated NSCLC Cell Lines, A549 and H460
Avinaba Mukherjee, Sandip Ghosh, Sayak Ganguli, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 4
Open Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Role of RAS signaling in ovarian cancer
Lubna Therachiyil, Anjana Anand, Abdullah Azmi, et al.
F1000Research (2022) Vol. 11, pp. 1253-1253
Open Access | Times Cited: 21
Genotype-specific precision tumor therapy using mitochondrial DNA mutation-induced drug release system
Y Li, Ru Xu, Yonghua Wu, et al.
Science Advances (2023) Vol. 9, Iss. 39
Open Access | Times Cited: 12
Universal and highly accurate detection of circulating tumor DNA mutation in non-small cell lung cancer based on CRISPR/Cas12a system
Xueliang Wang, Jian Song, Xiaoyu Fan, et al.
Sensors and Actuators B Chemical (2023) Vol. 383, pp. 133493-133493
Closed Access | Times Cited: 11
Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors
Xile Zhou, Yang Ji, Jinming Zhou
Molecules (2023) Vol. 28, Iss. 8, pp. 3615-3615
Open Access | Times Cited: 11
Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS
Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
Medical Oncology (2023) Vol. 40, Iss. 10
Open Access | Times Cited: 11
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
Joshua Zhang, Lily Darman, Mohammad Rashedul Hassan, et al.
Oncology Reports (2023) Vol. 50, Iss. 5
Open Access | Times Cited: 9
Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS
Lei Pan, Wanying Shen, Huijuan Tang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 1-12
Open Access | Times Cited: 3
MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction
Yunyun Dong, Yunqing Chang, Yu-Xiang Wang, et al.
BMC Bioinformatics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3

Scroll to top